Fig. 5: Diverse routes of JH-ENT-01 administration effectively reduce CFA-induced persistent inflammatory pain.
From: Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief
a–c Effects of intravenous injections of JH-ENT-01 (10 mg/kg, i.v.). a Schematic of drug injections and behavioral testing with PWT shown in b and PWF in c. n = 6 mice/group, equal number male and female). Figure 5a was created in BioRender. He, W. (2024) BioRender.com/f39n675. d–f Effects of subcutaneous injections of JH-ENT-01 (10 mg/kg, s.c.). d Schematic of drug injections and behavioral testing. Figure 5d was created in BioRender. He, W. (2024) BioRender.com/f05p763. e, f PWT shown in e and PWF in f. n = 6 mice/group equal number male and female mice. g–i Effects of intraplantar injections of JH-ENT-01 (10 μg). g Schematic of drug injections and behavioral testing in the CFA model. Created in BioRender. He, W. (2024) BioRender.com/j51a415. h, i PWT (h) and PWF (i) in the CFA model. n = 6 mice/group with equal number male and female mice. Two-way ANOVA followed by Bonferroni posthoc comparison (b, c, e, f, h, i). *P < 0.05, **P < 0.01, ***P < 0.001. All data were expressed as Mean ± SEM. BL baseline; CFA complete Freund’s adjuvant; PWF paw withdrawal frequency; PWT paw withdrawal threshold.
